TRENTON, NJ – January 22, 2010 — BioNJ, New Jersey’s trade association for the biotechnology community, announced today that the third annual Dr. Sol J. Barer Award for Vision, Innovation and Leadership has been awarded to John H. Johnson, President of Global Oncology and Senior Vice President of Eli Lilly and Company. Mr. Johnson was Chief Executive Officer of ImClone Systems prior to the company’s acquisition by Lilly in November 2008.
Named for Sol J. Barer, Ph.D., the Chairman and Chief Executive Officer of Celgene Corporation of Summit, N.J., the award recognizes outstanding research and business leaders who have made significant contributions to the growth and prosperity of the biosciences industry in New Jersey and throughout the world.
Dr. Barer will present the award to Mr. Johnson on January 28 during BioNJ’s Annual Meeting Dinner and Awards Program and Networking Event, which will be held from 5:00 p.m. to 10:00 p.m. at the Hilton East Brunswick. The meeting will bring together New Jersey’s biotechnology community to celebrate the efforts and contributions of the state’s companies to advance scientific innovation and improve patient care.
“John Johnson has made a tremendous impact on the biotechnology industry in New Jersey and throughout the United States in senior leadership roles with Johnson & Johnson, Pfizer, ImClone Systems, and now with Eli Lilly and Company,” said Debbie Hart, President of BioNJ. “From the earliest days of his career, Mr. Johnson has dedicated himself to efforts advancing the development of innovative biopharmaceutical treatments that have improved treatment outcomes and patient care around the world.”
About John H. Johnson, Eli Lilly and Company
John H. Johnson has more than two decades of executive and operational management experience in the biopharmaceutical and healthcare industries. Mr. Johnson currently serves as Senior Vice President and President, Global Oncology Business Unit, Eli Lilly and Company. Prior to this appointment in November 2009, he served as Chief Executive Officer of ImClone Systems since August 2007 and was also a member of ImClone’s Board of Directors until the company became a wholly-owned subsidiary of Lilly in 2008.
Prior to joining ImClone, Mr. Johnson served as Company Group Chairman of Johnson & Johnson’s Worldwide Biopharmaceuticals unit. In this executive role, he was responsible for the Johnson & Johnson Biotechnology, Immunology and Oncology commercial businesses, including Centocor, Inc., Ortho Biotech Products, L.P. and the Worldwide Strategic Marketing group.
Mr. Johnson began his healthcare career with Pfizer in 1983 where he held positions of increasing responsibility in sales and sales management. He joined Johnson & Johnson in 1988 to help lead their entry into the Anti-Infectives business. Mr. Johnson advanced through positions of increasing responsibility with Ortho-McNeil, including leading the commercial groups responsible for the development of sales, marketing and new product strategies of several of the company’s flagship brands, including LEVAQUIN®, ULTRAM® and TOPAMAX®. In 2000, he left Johnson & Johnson to assume the position of President and Chief Executive Officer for Parkstone Medical Information Systems. Mr. Johnson returned to Johnson & Johnson in 2002 as Worldwide Vice President, CNS/Psychiatry, for Johnson & Johnson Pharmaceuticals Group Strategic Marketing. He was appointed President of Ortho Biotech Products, L.P. in March 2003, and assumed responsibility for Ortho Biotech Canada in 2004. He held this position until being named Company Group Chairman in 2005.
Mr. Johnson received a B.S. degree from East Stroudsburg University of Pennsylvania. He currently serves on the boards of BioNJ and Cempra Pharmaceuticals, Inc.
About Sol J. Barer, Ph.D.
Dr. Barer has been CEO of Celgene, a global, integrated, biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases, since May 1, 2006 and Chairman since January 1, 2007. He was appointed President in 1993, Chief Operating Officer and Director in 1994 and is a member of the Executive Committee of the Board of Directors.
He founded the biotechnology group at Celanese that was subsequently spun out to form Celgene. Celgene is currently one of the world’s largest biotechnology companies with a market capitalization of over $20 Billion.
Dr. Barer is also on the Board of Trustees of Rutgers University, Board of Directors of PhRMA, serves as Secretary of the Board of Trustees of BioNJ, serves on the Board of Directors of Amicus Therapeutics and is on the Board of the Brooklyn College Foundation. He has previously served as a Commissioner of the NJ Commission on Science and Technology.
Dr. Barer received a Ph.D. in Organic Chemistry from Rutgers University.
In 2008, Dr. Barer was awarded the first Dr. Sol J. Barer Award for Vision, Innovation and Leadership. He also received the Lifetime Master Entrepreneur Award from Ernst & Young; The Hall of Distinguished Alumni Award of Rutgers University; the Corporate Vision Award from Gilda’s Club; and the Special Honoree Award from Community Hope. He has also received the Rutgers University Graduate School — 2007 Annual Distinguished Alumnus Award; the 2006 Winthrop-Sears Medal from the Chemists Club and the Chemical Heritage Foundation; the 2006 Corporate Leadership Award from The Multiple Myeloma Research Foundation; the Star Award of The Leukemia & Lymphoma Society; the 2005 Emerald Entrepreneurial and Excellence Award; the Albert Einstein Award in Life Sciences from Global Capital Associates and the Jerusalem Fund/Israel; the Insight Award from The Billy Foundation; and the DART/NYU Biotechnology Achievement Award in Applied Biotechnology.
About the Dr. Sol J. Barer Award for Vision, Innovation and Leadership
The Dr. Sol J. Barer Award for Vision, Innovation and Leadership was established by the BioNJ Board of Trustees in March 2008 as an annual award to recognize the outstanding research and business leaders who have made and continue to make significant contributions to the growth of the biosciences in New Jersey and around the world. The honoree is voted on by the BioNJ Board of Trustees from nominations taken from the Nominating Committee.
With 250 member companies, BioNJ (www.BioNJ.org) is singularly focused on the growth and prosperity of New Jersey’s bioscience cluster.
Founded in 1994 by New Jersey bioscience industry CEOs, BioNJ serves as the voice of bioscience companies located in New Jersey, seeks to advance their economic growth and development and works to encourage new and established companies from around the world to locate here. BioNJ represents companies engaged in biopharmaceutical, biomedical, bioagricultural and bioremedial endeavors.
# # #
CONTACT: Bill O’Donnell
Director of Public Affairs